Nisa Investment Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18M Sell
224,857
-1,648
-0.7% -$136K 0.07% 171
2025
Q4
$19.3M Sell
226,505
-18,806
-8% -$1.54M 0.06% 171
2025
Q3
$19.1M Sell
245,311
-7,746
-3% -$605K 0.07% 175
2025
Q2
$19.8M Sell
253,057
-5,605
-2% -$418K 0.09% 172
2025
Q1
$18.7M Sell
258,662
-1,955
-0.8% -$140K 0.09% 177
2024
Q4
$19.3M Buy
260,617
+12,351
+5% +$864K 0.07% 195
2024
Q3
$16.4M Sell
248,266
-13,271
-5% -$964K 0.1% 203
2024
Q2
$24.2M Sell
261,537
-16
-0% -$1.42K 0.15% 142
2024
Q1
$25M Buy
261,553
+573
+0.2% +$48.1K 0.16% 139
2023
Q4
$19.9M Sell
260,980
-2,343
-0.9% -$163K 0.14% 154
2023
Q3
$18.2M Sell
263,323
-2,580
-1% -$207K 0.14% 168
2023
Q2
$25.1M Buy
265,903
+360
+0.1% +$31.3K 0.18% 121
2023
Q1
$22M Buy
265,543
+8,583
+3% +$675K 0.17% 130
2022
Q4
$19.2M Sell
256,960
-12,046
-4% -$928K 0.15% 159
2022
Q3
$22.2M Sell
269,006
-2,324
-0.9% -$224K 0.19% 118
2022
Q2
$25.8M Sell
271,330
-40
-0% -$4.14K 0.23% 100
2022
Q1
$31.9M Sell
271,370
-11,116
-4% -$1.25M 0.23% 96
2021
Q4
$30.8M Sell
282,486
-25,323
-8% -$2.95M 0.23% 102
2021
Q3
$34.8K Sell
307,809
-5,420
-2% -$619K 0.21% 98
2021
Q2
$32.4K Sell
313,229
-16,565
-5% -$1.56M 0.2% 99
2021
Q1
$27.6K Sell
329,794
-7,070
-2% -$598K 0.18% 118
2020
Q4
$30.7M Buy
336,864
+404
+0.1% +$33.5K 0.2% 120
2020
Q3
$26.9M Sell
336,460
-62,819
-16% -$4.9M 0.22% 107
2020
Q2
$27.6M Buy
399,279
+61,755
+18% +$4.39M 0.25% 85
2020
Q1
$21.2M Sell
337,524
-31,599
-9% -$2.28M 0.24% 99
2019
Q4
$28.7M Buy
369,123
+11,754
+3% +$918K 0.25% 89
2019
Q3
$26.2M Buy
357,369
+1,953
+0.5% +$137K 0.23% 95
2019
Q2
$21.9M Sell
355,416
-11,574
-3% -$700K 0.21% 103
2019
Q1
$23.4M Buy
366,990
+20,691
+6% +$1.18M 0.23% 98
2018
Q4
$17.7M Buy
346,299
+9,426
+3% +$477K 0.2% 116
2018
Q3
$19.5M Buy
336,873
+29,757
+10% +$1.46M 0.18% 133
2018
Q2
$14.9M Buy
307,116
+7,770
+3% +$363K 0.15% 153
2018
Q1
$13.9M Buy
299,346
+6,450
+2% +$280K 0.15% 158
2017
Q4
$11M Sell
292,896
-13,200
-4% -$484K 0.11% 188
2017
Q3
$11.2M Buy
306,096
+4,500
+1% +$172K 0.13% 181
2017
Q2
$11.9M Buy
301,596
+67,200
+29% +$2.45M 0.14% 164
2017
Q1
$7.35M Sell
234,396
-9,825
-4% -$308K 0.09% 244
2016
Q4
$7.63M Sell
244,221
-6,792
-3% -$220K 0.09% 227
2016
Q3
$10.1M Buy
251,013
+9,600
+4% +$362K 0.13% 185
2016
Q2
$8.03M Buy
241,413
+10,785
+5% +$369K 0.11% 212
2016
Q1
$6.78M Buy
230,628
+13,500
+6% +$372K 0.1% 220
2015
Q4
$5.72M Buy
217,128
+2,400
+1% +$62.3K 0.08% 244
2015
Q3
$5.09M Buy
214,728
+600
+0.3% +$14.5K 0.08% 263
2015
Q2
$5.08M Hold
214,128
0.07% 283
2015
Q1
$5.08M Buy
214,128
+19,800
+10% +$444K 0.07% 287
2014
Q4
$4.13M Sell
194,328
-252
-0.1% -$5.06K 0.06% 344
2014
Q3
$3.31M Sell
194,580
-9,600
-5% -$152K 0.05% 392
2014
Q2
$2.92M Hold
204,180
0.04% 441
2014
Q1
$2.52M Hold
204,180
0.04% 481
2013
Q4
$2.24M Sell
204,180
-42,600
-17% -$480K 0.03% 509
2013
Q3
$2.86M Hold
246,780
0.04% 402
2013
Q2
$2.76M Buy
+246,780
New +$2.92M 0.04% 409

Other funds holding EW

Nisa Investment Advisors's EW Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Edwards Lifesciences (EW) stake by 0.73% in Q1 2026, selling an estimated $136K and leaving 224,857 shares worth $18M. The position accounts for 0.07% of the portfolio, ranked #171.

Nisa Investment Advisors first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $31.9M in Q1 2022. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Nisa Investment Advisors held 224,857 shares of Edwards Lifesciences worth $18M as of Q1 2026.
  • Nisa Investment Advisors sold 1,648 Edwards Lifesciences shares in Q1 2026, an estimated $136K.
  • Edwards Lifesciences made up 0.07% of Nisa Investment Advisors's portfolio in Q1 2026, its #171 holding.
  • Nisa Investment Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Nisa Investment Advisors's Edwards Lifesciences position peaked at $31.9M in Q1 2022.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.